These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 6313195

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M, Dickgiesser N, Müller S, Wundt W.
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antimicrobial activity of ceftriaxone: a review.
    Cleeland R, Squires E.
    Am J Med; 1984 Oct 19; 77(4C):3-11. PubMed ID: 6093515
    [Abstract] [Full Text] [Related]

  • 26. [In vitro bacteriostatic activity of cefmenoxime (SCE 1365), cefotaxime and moxalactam].
    Husson MO, Bryskier A, Izard D, Leclerc H.
    Pathol Biol (Paris); 1983 May 19; 31(5):347-50. PubMed ID: 6312395
    [Abstract] [Full Text] [Related]

  • 27. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P, Bryskier A, Le Noc D.
    Pathol Biol (Paris); 1985 May 19; 33(5):399-403. PubMed ID: 3897972
    [Abstract] [Full Text] [Related]

  • 28. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A, Meyran M, Huerre M.
    Pathol Biol (Paris); 1985 May 19; 33(5):404-7. PubMed ID: 3929217
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.
    Emmerson AM, Lamport PA, Reeves DS, Bywater MJ, Holt HA, Wise R, Andrews J, Hall MJ.
    Curr Med Res Opin; 1985 May 19; 9(7):480-93. PubMed ID: 3928265
    [Abstract] [Full Text] [Related]

  • 32. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G, Johnston J, Young LS, Martin WJ.
    J Antimicrob Chemother; 1981 Sep 19; 8 Suppl B():83-9. PubMed ID: 19810170
    [Abstract] [Full Text] [Related]

  • 33. [In vitro activity of cefatiolene (RP 42,980) against hospital bacteria. Comparison with cefotaxime and lamoxactam. Results of a multicenter study].
    Duval J, Soussy CJ, Deforges L, Le Van Thoi J, Acar JF, Kitzis D, Dabernat H, Christol D, Bure A, Courtieu AL.
    Pathol Biol (Paris); 1983 May 19; 31(5):357-61. PubMed ID: 6312397
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
    Hall WH, Opfer BJ, Gerding DN.
    Antimicrob Agents Chemother; 1980 Feb 19; 17(2):273-9. PubMed ID: 6247970
    [Abstract] [Full Text] [Related]

  • 36. In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.
    Fass RJ.
    Arch Intern Med; 1980 Jun 19; 140(6):763-8. PubMed ID: 7387270
    [Abstract] [Full Text] [Related]

  • 37. [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams].
    Jarlier V, Bismuth R, Grosset J.
    Pathol Biol (Paris); 1983 May 19; 31(5):336-42. PubMed ID: 6312393
    [Abstract] [Full Text] [Related]

  • 38. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
    Bell JM, Turnidge JD, Cefepime Study Group.
    Pathology; 2001 Feb 19; 33(1):53-60. PubMed ID: 11280610
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.